

Generic aciphex approved to treat chronic heartburn

November 8 2013

(HealthDay)—The first generic versions of the anti-GERD drug Aciphex (rabeprazole sodium) have been approved by the U.S. Food and Drug Administration for people aged 12 and older, the agency said Friday.

Gastroesophageal reflux disease (GERD), also known as chronic heartburn, is a very common disorder characterized by backward flow of stomach acid to the esophagus. This process could damage tissue in the esophagus, the tube that connects the throat and stomach.

License to produce generic rabeprazole was granted to Dr. Reddy's Laboratories, Kremers Urban Pharmaceuticals, Lupin Pharmaceuticals, Mylan Pharmaceuticals, Teva Pharmaceuticals and Torrent Pharmaceuticals, the FDA said.

The drug is among a class called proton-pump inhibitors, which are designed to reduce the amount of stomach acid produced. Generic drugs, the FDA stressed, are equivalent to the brand-name versions in strength and quality.

More information: To learn more about GERD, visit Medline Plus.

Copyright © 2013 HealthDay. All rights reserved.

Citation: Generic aciphex approved to treat chronic heartburn (2013, November 8) retrieved 5



May 2024 from https://medicalxpress.com/news/2013-11-aciphex-chronic-heartburn.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.